TOKYO -- Asian investment fund MBK Partners will buy Japan's Alinamin Pharmaceutical, a maker of supplements and nonprescription drugs, from Blackstone Group for an estimated 350 billion yen ($2.2 billion), Nikkei learned Tuesday.
MBK, which has experience in consumer goods with such acquisitions as Godiva's Asia-Pacific business and jewelry maker Tasaki, aims to use this know-how to boost Alinamin's value.
